31 January 2013 – The Brighton Marathon, to be held on 14 April, will be the world’s first mass participation sports event to use the RhinoChill® IntraNasal Cooling System.
Marathon runners can suffer a cardiac arrest - although thankfully this is an extremely rare event. It is becoming increasingly recognised that cooling the brain (therapeutic hypothermia) following cardiac arrest can improve the chances of survival and minimise any long-term neurological damage – and that these benefits will be more pronounced the earlier and more effectively that therapeutic hypothermia can be induced.
RhinoChill induces therapeutic hypothermia more rapidly, effectively and easily than conventional cooling systems. It is a non-invasive, simple to use device which quickly and effectively reduces brain temperature by spraying an evaporating coolant liquid up the nose and into the nasal cavity, a large area situated under the brain which acts as a heat exchanger. “Hopefully, we will never have to use the equipment,” commented Brighton Marathon’s Medical Director, Rob Galloway. “But if the occasion does ever happen, we know that we have the most advanced and up-to-date equipment available to deal with post cardiac arrest patients.”
This year’s Brighton Marathon is anticipated to attract around 10,000 participants. It is the third largest marathon event in the UK, behind only London and Edinburgh.
For further information, please contact:
Richard Kenyon, RKPR: +44 7831 569940; richard@rkpr.co.uk
About The RhinoChill® IntraNasal Cooling System (www.rhinochill.com)
The RhinoChill® IntraNasal Cooling System is a portable, non-invasive and easy-to-use system for rapidly and effectively inducing therapeutic hypothermia following an acute ischemic event such as cardiac arrest, stroke or traumatic brain injury, thereby increasing neurologically intact survival rates. Unlike conventional cooling systems, RhinoChill use can be initiated at the site of the event, and then continued in the ambulance and when the patient has reached hospital.
RhinoChill received CE Mark approval in December 2007, and is now available in selected European markets. The current focus for RhinoChill’s use is with Accident and Emergency Units, Cath Labs, Intensive Care Departments and Ambulance Services.
